AU2021288056A1 - Sulcardine administration for treatment of acute atrial fibrillation - Google Patents

Sulcardine administration for treatment of acute atrial fibrillation Download PDF

Info

Publication number
AU2021288056A1
AU2021288056A1 AU2021288056A AU2021288056A AU2021288056A1 AU 2021288056 A1 AU2021288056 A1 AU 2021288056A1 AU 2021288056 A AU2021288056 A AU 2021288056A AU 2021288056 A AU2021288056 A AU 2021288056A AU 2021288056 A1 AU2021288056 A1 AU 2021288056A1
Authority
AU
Australia
Prior art keywords
sulcardine
pharmaceutically acceptable
acceptable salt
administration
tmax
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021288056A
Other languages
English (en)
Inventor
Gary Elliott
Mireille GILLINGS
Robert Goodenow
Jay Mason
Waldemar RADZISZEWSKI
Suzanne ROMANO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huyabio International LLC
Original Assignee
Huyabio International LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huyabio International LLC filed Critical Huyabio International LLC
Publication of AU2021288056A1 publication Critical patent/AU2021288056A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021288056A 2020-06-12 2021-06-11 Sulcardine administration for treatment of acute atrial fibrillation Pending AU2021288056A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063038664P 2020-06-12 2020-06-12
US63/038,664 2020-06-12
PCT/US2021/037098 WO2021252959A1 (en) 2020-06-12 2021-06-11 Sulcardine administration for treatment of acute atrial fibrillation

Publications (1)

Publication Number Publication Date
AU2021288056A1 true AU2021288056A1 (en) 2023-02-09

Family

ID=78824214

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021288056A Pending AU2021288056A1 (en) 2020-06-12 2021-06-11 Sulcardine administration for treatment of acute atrial fibrillation

Country Status (14)

Country Link
US (2) US11813245B2 (cg-RX-API-DMAC10.html)
EP (1) EP4164633A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023529196A (cg-RX-API-DMAC10.html)
KR (1) KR20230024347A (cg-RX-API-DMAC10.html)
CN (1) CN116723836A (cg-RX-API-DMAC10.html)
AU (1) AU2021288056A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022025216A2 (cg-RX-API-DMAC10.html)
CA (1) CA3182015A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022003501A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023000194A2 (cg-RX-API-DMAC10.html)
IL (1) IL298907A (cg-RX-API-DMAC10.html)
MX (1) MX2022015834A (cg-RX-API-DMAC10.html)
PH (1) PH12022553396A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021252959A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11813245B2 (en) * 2020-06-12 2023-11-14 Huyabio International, Llc Sulcardine administration for treatment of acute atrial fibrillation
WO2026036095A1 (en) * 2024-08-08 2026-02-12 Huyabio International, Llc J-Tp PROTECTION

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1172908C (zh) * 1999-12-10 2004-10-27 中国科学院上海药物研究所 N-取代苄基或苯基芳香磺酰胺化合物及其用途
CN1939298A (zh) 2005-09-29 2007-04-04 中国科学院上海药物研究所 硫酸舒欣啶固体和靶向制剂及其制备方法
US8541464B2 (en) * 2009-11-17 2013-09-24 HUYA Biosciences International LLC Treatment of atrial fibrillation
WO2011062903A2 (en) * 2009-11-17 2011-05-26 Elliott Gary T Slow infusion of sulcardine and its salts
EP3302442B1 (en) 2015-06-03 2024-10-16 Triastek, Inc. Dosage forms and use thereof
AU2017261372B2 (en) 2016-05-05 2019-02-14 Triastek, Inc. Controlled release dosage form
AU2018212273B2 (en) 2017-01-26 2023-12-21 Triastek, Inc. Dosage forms of controlled release at specific gastrointestinal sites
WO2020123824A1 (en) * 2018-12-13 2020-06-18 Huya Bioscience International, Llc Sulcardine administration for treatment of acute atrial fibrillation
KR102405199B1 (ko) * 2019-01-29 2022-06-02 후야 바이오사이언스 인터내셔널 엘엘씨 설카딘 염
US11813245B2 (en) * 2020-06-12 2023-11-14 Huyabio International, Llc Sulcardine administration for treatment of acute atrial fibrillation

Also Published As

Publication number Publication date
US11813245B2 (en) 2023-11-14
US20240058304A1 (en) 2024-02-22
PH12022553396A1 (en) 2024-04-22
IL298907A (en) 2023-02-01
EP4164633A4 (en) 2024-07-31
WO2021252959A1 (en) 2021-12-16
JP2023529196A (ja) 2023-07-07
CL2022003501A1 (es) 2023-06-09
KR20230024347A (ko) 2023-02-20
BR112022025216A2 (pt) 2023-04-04
EP4164633A1 (en) 2023-04-19
US12465587B2 (en) 2025-11-11
CN116723836A (zh) 2023-09-08
US20210386708A1 (en) 2021-12-16
CO2023000194A2 (es) 2023-03-27
CA3182015A1 (en) 2021-12-16
MX2022015834A (es) 2023-04-04

Similar Documents

Publication Publication Date Title
US11883380B2 (en) Sulcardine administration for treatment of acute atrial fibrillation
US12465587B2 (en) Sulcardine administration for treatment of acute atrial fibrillation
EP2133074A1 (en) Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation
KR20160108611A (ko) 심방세동의 치료 방법
US8541464B2 (en) Treatment of atrial fibrillation
EP2133075A1 (en) Use of dronedarone for the preparation of a medicament intended for the prevention of cardioversion
JP2011517694A (ja) ドロネダロンと少なくとも１つの利尿薬の組み合わせおよびこの治療的使用
US20260041665A1 (en) J-Tp Protection
EA045624B1 (ru) Введение сулькардина для лечения острой фибрилляции предсердий
EP2386300A1 (en) Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality in patients having a first recurrence of atrial fibrillation or atrial flutter
HK40061591A (en) Sulcardine administration for treatment of acute atrial fibrillation
EP2387996A1 (en) Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events in patients with permanent atrial fibrillation
EP3836918A1 (en) Task-1 inhibitors for treatment of atrial arrhythmias
HK1155667A (en) Dronedarone for the prevention of cardioversion
HK1156503A (en) Combination of dronedarone with at least one diuretic, and therapeutic use thereof
TW201200131A (en) Use of dronedarone for the preparation of a medicament for the prevention of cardiovacular hospitalizations or death or cardiovascular events in patients with premanent atrial fibrillation
HK1176859A (en) Treatment of atrial fibrillation
HK1176859B (en) Treatment of atrial fibrillation